STAT Plus: Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’
ORLANDO, Fla. — In June, Dr. Samit Hirawat was appointed chief medical officer of Bristol-Myers…
Category: Business
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
ORLANDO, Fla. — One year ago, a Chinese scientist stepped up to a podium at…
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
ORLANDO, Fla. — On the eve of a major blood disease research meeting here, Bluebird…
.jpg)
How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy
Building a health-technology startup on nothing but hot air may be easier than you’d think…
Global Blood secures FDA approval for new pill to treat sickle cell disease
The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease…
STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
A group of leading Boston-area universities, hospitals, and corporations will create a new center for…
With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days…
STAT Plus: Patient charity settles allegations it helped MS drug makers pay kickbacks
A patient assistance charity has agreed to pay $4 million to settle allegations that it…